Proteome Sciences set to feed new biomarkers to Dx firms
This article was originally published in Clinica
Executive Summary
A UK company with high-sensitivity technology to analyse proteins and a strong focus on applying this to help partners accelerate development of diagnostic, prognostic and therapeutic products has carved out a unique niche for itself in the life sciences market. Eleanor Malone visited Proteome Sciences to find out more.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.